目的 探討康艾注射液聯(lián)合鹽酸?？颂婺崞委熗砥诜切〖?xì)胞肺癌的臨床療效。方法 選取2013年5月-2018年5月在洛陽(yáng)市第三人民醫(yī)院就診的82例晚期非小細(xì)胞肺癌患者，隨機(jī)分為觀察組（n=41）和對(duì)照組（n=41）。對(duì)照組給予患者口服鹽酸?？颂婺崞?，3次/d，125 mg/次。觀察組在對(duì)照組基礎(chǔ)上給予康艾注射液40 mL，1次/d。兩組均治療1個(gè)月。對(duì)比兩組治療效果、生活質(zhì)量和毒副作用發(fā)生率。結(jié)果 與對(duì)照組治療總有效率12.20%和病情控制率48.78%比較，觀察組治療總有效率31.71%和病情控制率85.37%均顯著升高（P<0.05）。兩組呼吸困難、便秘、食欲缺乏發(fā)生率，角色功能、認(rèn)知功能、社會(huì)功能評(píng)分及毒副作用（肝功能異常和腹瀉）發(fā)生率比較，差異均無(wú)統(tǒng)計(jì)學(xué)意義。觀察組疲倦、疼痛和皮疹發(fā)生率均顯著低于對(duì)照組（P<0.05）；軀體功能、情緒功能評(píng)分均顯著高于對(duì)照組（P<0.05）。結(jié)論 康艾注射液聯(lián)合鹽酸埃克替尼片治療晚期非小細(xì)胞肺癌療效顯著，且安全性良好，值得臨床推廣。

Objective To investigate the clinical efficacy of Kang Ai Injection combined with Icotinib Hydrochloride Tablets in the treatment of advanced non-small cell lung cancer (NSCLC).Methods 82 patients with advanced NSCLC from May 2013 to May 2018 were randomly divided into observation group (icotinib hydrochloride+Kang Ai Injection,n=41) and control group (icotinib hydrochloride,n=41).The therapeutic effect,quality of life and incidence of side effects were compared between the two groups.Results The total effective rate 31.71% and disease control rate 85.37% in the observation group were significantly higher than those in the control group (12.20%&48.78%)(P<0.05).There was no significant difference in the incidence of dyspnea,constipation,anorexia,role function,cognitive function and social function score,incidence of toxic side effects (abnormal liver function and diarrhea) between the two groups.The incidence of fatigue,pain and rash in the observation group were significantly lower than those in the control group (P<0.05),and the scores of physical function and emotional function were significantly higher than those in the control group (P<0.05).Conclusion Kang Ai Injection combined with Icotinib Hydrochloride Tablets is effective and safe in the treatment of advanced NSCLC.